119 related articles for article (PubMed ID: 22252621)
21. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
22. Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.
Costa LJ
Br J Haematol; 2009 Sep; 146(5):576-7. PubMed ID: 19555375
[No Abstract] [Full Text] [Related]
23. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Watanabe A; Chansu S; Ogawa A; Asami K; Imamura M
Pediatr Int; 2013 Jun; 55(3):e56-8. PubMed ID: 23782380
[TBL] [Abstract][Full Text] [Related]
24. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia.
Sun J; Wang Z; Luo Y; Tan Y; Allan DS; Huang H
Acta Haematol; 2012; 127(3):143-8. PubMed ID: 22248505
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors.
Abou Mourad YR; Fernandez HF; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2008 Sep; 14(9):949-958. PubMed ID: 18721758
[TBL] [Abstract][Full Text] [Related]
26. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
[TBL] [Abstract][Full Text] [Related]
27. Reversible cardiotoxicity with tyrosine kinase inhibitors.
Francis J; Ahluwalia MS; Wetzler M; Wang E; Paplham P; Smiley S; McCarthy PL; Cohen IL; Spangenthal E; Battiwalla M
Clin Adv Hematol Oncol; 2010 Feb; 8(2):128-32. PubMed ID: 20386534
[No Abstract] [Full Text] [Related]
28. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
[TBL] [Abstract][Full Text] [Related]
29. Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Cannella L; Loglisci G; Nanni M; De Cuia MR; Colafigli G; Salaroli A; Serrao A; Alimena G; Breccia M
Leuk Lymphoma; 2012 Mar; 53(3):497-8. PubMed ID: 21854086
[No Abstract] [Full Text] [Related]
30. Efficacy of hematopoietic stem cell transplantation and prophylactic triple intrathecal therapy in a child with multiple CNS relapse of acute lymphoblastic leukemia.
Tavil B; Ayçicek A; Azik F; Tunc B; Del Castello BE; Uçkan D
Clin Transplant; 2013; 27(4):E346-7. PubMed ID: 23781848
[No Abstract] [Full Text] [Related]
31. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
32. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
[No Abstract] [Full Text] [Related]
33. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
de Castro CG; Gregianin LJ; Meneses CF; Brunetto AL
Pediatr Blood Cancer; 2009 Dec; 53(6):1161. PubMed ID: 19621456
[No Abstract] [Full Text] [Related]
35. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
Glover JM; Loriaux M; Tyner JW; Druker BJ; Chang BH
Pediatr Blood Cancer; 2012 Sep; 59(3):576-9. PubMed ID: 22038978
[TBL] [Abstract][Full Text] [Related]
36. Ph+ ALL: imatinib grows older with patients.
Bassan R
Blood; 2014 Feb; 123(6):801-3. PubMed ID: 24505064
[No Abstract] [Full Text] [Related]
37. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
Takayama N; Sato N; O'Brien SG; Ikeda Y; Okamoto S
Br J Haematol; 2002 Oct; 119(1):106-8. PubMed ID: 12358909
[TBL] [Abstract][Full Text] [Related]
38. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
Fava C; Rege-Cambrin G; Busca A; Gottardi E; Daraio F; Saglio G
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S272-5. PubMed ID: 24290212
[No Abstract] [Full Text] [Related]
39. Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant.
Martin SE; DellaValla J
Leukemia; 2005 Jun; 19(6):1095-6. PubMed ID: 15789065
[No Abstract] [Full Text] [Related]
40. Imatinib for relapsed BCR/ABL positive leukemias.
Ottmann OG; Wassmann B; Hoelzer D
Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
